

DATE

**FAX FORM TO**: 1.877.597.3070 | **PHONE**: 1.800.473.3516 | **EMAIL**: specialty@wellpartner.com

Complete the following or include demographic sheet.

DISPENSE AS WRITTEN

1. PATIENT INFORMATION			2. PRESCRIBER INFORMATION			
Name:			Name:			
Address:			DEA #: NPI #:	: State Lic. #:		
City, State, ZIP:			Group or Hospital:			
Primary Phone: DOB: / /			Address:			
Alternate Phone: Gender:			City, State, Zip:			
Email:			Phone: Fax:			
Primary Language: Last Four of SSN:		Contact Person: Phone:				
3. INSURAN	ICE INFORMATION	Fax copy of <b>presc</b> i	ription and insurance cards with	n this form, if available (front and	d back)	
Primary Insurance Company Name:			Secondary Insurance Company Name:			
Primary Cardholder Name:			Secondary Cardholder Name:			
Relationship: O Self O Spouse/Partner O Child/Dependent			Relationship: O Self O Spouse/Partner O Child/Dependent			
Phone: Member ID: Group #:			Phone:	Member ID: Group #:		
4. DIAGNOS	SIS AND CLINICAL INFORMAT	ION				
Needs by Date: / / Ship to: OPatient			Office Other:			
Date of Diagnosis: / / Does the patient have a hi			istory of osteoporotic fracture?			
		16 ' 1	patient failed or is unable to tolerate other previous osteoporosis therapy?			
M81.8 Other osteoporosis w/o fracture Does th			oes the patient have more than one risk factor for fracture? O Yes O No			
Mobile Other osteoporosis w/ fracture		If yes, please explain:				
O outlot.		Will the patient be taking	Il the patient be taking Forteo in combination with a bisphosphonate? Yes No			
Height (in/cm): Weight (lb/kg):  Allergies:		· ·	Has the patient received Forteo in the past?  Yes  No  If yes, have they received more than 24 months total therapy with Forteo?  Yes  No			
, mot gross		Does the patient have any	Does the patient have any of the following contraindications to Forteo use:			
			Prior radiation therapy  Pro-evicting hypercal cemia malignancy			
Current Medications:		involving the skeleton	Thorradiation therapy Tre-existing hypercateernia			
		Metaboloic bone dise	Metaboloic bone disease of alkaline phosphatase other than osteoporosis			
5. PRESCRI	PTION INFORMATION					
Medication	Dose/Strength	Directions		Quantity	Refills	
O Boniva	3 mg/3 ml prefilled syringe	Inject contents of one syringe     Other:	e (3mg) via IV once every 3 months	1 syringe (3-month supply) Other:		
○ Forteo	600 mcg/2.4 ml delivery device	Inject 20 mcg (0.08 ml) SQ once	daily.	1 device (4-week supply) 3 devices (12-week supply)		
Needles - 31 gauge Use with Forted  5 mm 6 mm 8 mm		Use with Forteo delivery device a	as directed.	4-week supply 12-week supply		
O Prolia	60 mg/1 ml prefilled syringe	Inject 60 mg subcutaneously     Other:	v every 6 months.			
Reclast	5mg/100ml vial	Infuse 5mg IV once a year		1 vial		
0						
Ancillary supplie	s and kits will be provided as need	led for administration.		I	1	
6. PRESCRI	BER SIGNATURE					
y / / y						

PRODUCT SUBSTITUTION PERMITTED

DATE